Novel Food Basics: What to Check Before You Formulate

Novel food status is not a judgment about whether an ingredient is safe, popular or well studied. It is a narrow legal test: was this ingredient, in this form, consumed by people to a significant degree before a fixed cutoff date, in the EU's case 15 May 1997. If the answer is no, or cannot be confirmed, the ingredient is treated as novel regardless of how established it feels in the wider market.

That test applies to a specific ingredient in a specific form, not to a category of food in general. Two forms of what most people would call the same plant or nutrient can land on different sides of that line if one form's consumption history before the cutoff can be shown and the other's cannot.

What follows is a planning-level orientation to that test, not a determination for any specific ingredient. Confirming novel-food status for a specific ingredient and form is a job for a qualified regulatory adviser working from the actual dossier and evidence base, not something a general orientation can resolve on its own.

Consumer familiarity and regulatory history are two different things, and the gap between them is where most surprises happen. An ingredient can be sold widely in supplement form in one country while still lacking a documented pre-cutoff consumption history in the EU's specific sense, which is the only history the novel-food test actually looks at.

The test can also turn on how an ingredient is produced or presented rather than what it fundamentally is. A new extraction method, a significantly different concentration of the active compound, or a novel production process applied to an otherwise ordinary source material can each be enough to trigger novel status, even where the raw source material itself is unquestionably traditional.

None of this means an ingredient is unusable. It means the consumption-history question has to be checked and documented for the specific form you plan to formulate with, rather than assumed from how established the ingredient feels, or from how it is already being sold somewhere else.

Where an ingredient's novel-food status is unresolved and a brand wants to use it anyway, the route runs through a formal application: a safety dossier submitted to the relevant authority, followed by a scientific safety assessment before any authorisation is granted. That process sits entirely outside a brand's own production timeline and follows the authority's own schedule, not the brand's launch date.

This is worth stating plainly because it is easy to conflate with production planning: a novel-food authorisation is not something a manufacturing partner can expedite or influence, and it is not booked, scheduled or confirmed the way a production slot is. It is a separate regulatory process running on its own clock.

A brand can commission its own dossier, join an existing application already filed by another party for the same ingredient, or wait for a decision already in progress to land, and each of those three paths carries a different level of control and a different level of dependency on someone else's timeline. Which path fits a given project is a question for a regulatory adviser, not something the formulation brief can settle on its own.

For a brand scoping a new formulation, the practical takeaway is sequencing: know whether your target ingredient's status is already resolved before you build a launch calendar around it, rather than discovering mid-project that the ingredient you have already committed to needs its own authorisation process first.

The UK operates its own novel-food framework, separate from the EU's, and the two do not automatically recognise each other's decisions. An ingredient authorised as novel food for the EU market is not automatically authorised for the UK market, and the reverse holds equally: a UK authorisation does not carry across the Channel into the EU.

For a brand planning to launch the same formula into both the UK and the EU, this means the novel-food question is checked twice, once against each framework, rather than once and assumed to cover both markets. That is the same divergence pattern that shows up across UK and EU supplement rules more broadly, applied specifically to this one question.

Where a formula is intended for both markets from the start, checking novel-food status against both frameworks at the brief stage, before a formula is finalised, is considerably cheaper than discovering a mismatch after one market's production run is already underway.

An ingredient with a clear, documented pre-cutoff history moves through a formulation brief at the same pace as any other confirmed ingredient. An ingredient whose novel-food status is unresolved does not, because the authorisation process described above is not something a launch calendar can simply schedule around.

This is the main reason to check novel-food status before, not after, a brief is written around a specific ingredient. A brief built on an unresolved novel-food question is a brief with an open-ended dependency sitting inside it, and that dependency does not resolve itself just because the rest of the project is ready to move.

Where status is genuinely unclear, the practical options are usually to confirm it before committing further, to substitute a documented alternative that delivers a similar profile, or to accept that the ingredient sits on a longer, separate timeline from the rest of the launch and plan the wider range around that reality rather than against it.

Start with the EU's own novel food catalogue and the UK's equivalent register, which list ingredients whose status has already been determined one way or the other. An ingredient not listed at all is not automatically safe from novel-food status; absence from the list means the question has not been formally settled, not that it has been settled in the brand's favour.

Where an ingredient sits in that ambiguous space, neither clearly listed as authorised nor clearly listed as requiring authorisation, treat that as a stop-and-check moment rather than a reason to proceed on the assumption that it will probably be fine. A regulatory adviser working from the specific form and intended use is the right party to resolve that ambiguity.

Ask the same question of an extract or concentrate that you would ask of the raw source material: is this exact form, at this exact concentration, the thing with the documented pre-cutoff history, or is it a step removed from it. A supplier who can point to that history for the precise form being used has already done useful groundwork; a supplier who can only speak to the traditional raw material has not answered the question the novel-food test actually asks.

Build the check into the brief stage as a standing item, before a formula is sampled and well before it is locked for production, so an unresolved status is caught while switching an ingredient or adjusting a formulation concept is still a straightforward edit rather than a late-stage rebuild.

Confirming novel-food status, and any notification or authorisation that follows from it, remains the brand owner's responsibility, working with their own regulatory adviser; a manufacturing partner can flag a known novel-food-status ingredient during brief review, but does not make the underlying regulatory determination on the brand owner's behalf.

The production side of a formulation project runs on the same commercial terms regardless of an ingredient's novel-food status. The private-label route starts from 1,000 units for a standard PET bottle or 2,500 units for doypack packaging, and Make it Yours changes flavour, colour or shape on an existing formula, while a genuinely new active, including a novel-food ingredient being introduced for the first time, moves the project into Custom Formula R&D instead.

Lead time for production itself is a planning range of 5–12 weeks depending on format, packaging, production slot and destination, confirmed during order setup, and that clock only starts once the formula itself, including any novel-food question, is settled and ready to move forward.

Write the novel-food check into the brief as its own line item, with its own owner and its own resolution date, for any ingredient that is new to your range or unusual in its sourcing or processing. Treating it as a standing question rather than an assumption is the single change that prevents most of the mid-project surprises a novel-food gap tends to cause.

Where status is already confirmed for your specific ingredient and form, say so explicitly in the brief along with the source of that confirmation, so a manufacturing partner and your own regulatory adviser are working from the same starting point rather than each assuming someone else already checked.

A formulation brief that states the target markets, the ingredient list and the novel-food status of anything unusual on that list up front gives a manufacturing partner a clean, well-scoped project to plan production against, while the underlying regulatory question is confirmed on its own track by the people responsible for it.